Anti‐diabetic effects of GLP ‐1 receptor agonists on obese and overweight patients across diabetes status, administration routes, treatment duration and baseline characteristics: A systematic review
Authors' conclusion
Overall, GLP-1 RAs consistently led to a significant reduction in HbA1c at -0.72% and FPG at -1.00 mmol/L. These effects may be equally efficacious in pre-DM patients with obesity and those at lower BMI.
Study context
- Population
- Adults >18 years with overweight/obesity, with or without T2D; RCTs from PubMed, EMBASE and CENTRAL, inception to 13 February 2024
- Comparison
- GLP-1 RAs
- Outcome
- Change in HbA1c and FPG
Methodological detailsPubMed, EMBASE and CENTRAL searched from inception to 13 February 2024
- PubMed, EMBASE and CENTRAL searched from inception to 13 February 2024
Pooled result
As reported in the abstract
Overall reduction in HbA1c
−0.72%
95% CI −0.79 to −0.65p < 0.01
Overall reduction in fasting plasma glucose (FPG)
−1.00 mmol/L
95% CI −1.16 to −0.84p < 0.01
Further pooled results
HbA1c reduction in pre-DM patients
- HbA1c reduction in pre-DM
- −0.44% (95% CI −0.54 to −0.18, p < 0.01)
HbA1c reduction by follow-up duration · more than a year
- Follow-up >1 year: smaller reduction of HbA1c
Meta-regression
- GLP-1 RAs more efficacious at higher HbA1c and lower BMI
Original publication
Anti‐diabetic effects of GLP ‐1 receptor agonists on obese and overweight patients across diabetes status, administration routes, treatment duration and baseline characteristics: A systematic review. Diabetes Obes Metab. Published 26 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →